Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05779007 · ClinicalTrials.gov registry record
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 2,778
- Enrollment target
NCT05779007: Completed study, sponsored by Boehringer Ingelheim.
NCT05779007 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,778 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05779007 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 2,778 participants
- Enrollment target
Study Summary
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
Primary Outcome
Number of patients with sub-optimal dose was be defined as patients with an average daily dose not following the prescribing information of nintedanib and pirfenidone for at least 90 consecutive days, corresponding to ≤ 66.67% dose strength for pirfenidone and ≤ 66.67% dose strength for nintedanib. Number of patients with sub-optimal dosing by month 12 is reported.
Interventions
- DRUG Pirfenidone
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,778 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2023-07-14 |
What the finished NCT05779007 record still lists
NCT05779007 is an observational study that tracks outcomes without assigning an intervention. Its 2,778 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Pirfenidone is the first listed.
NCT05779007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05779007 about?
NCT05779007 is a clinical study titled "Dose Reduction and Discontinuation With Anti-Fibrotic Medications". The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
What is the current status of trial NCT05779007?
This trial is currently completed. The enrollment target is 2,778 participants. The study started on 2023-04-18. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05779007?
The interventions under investigation include: Pirfenidone (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05779007?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI